Centre Oscar Lambret, a cancer treatment centre in France, has selected ViewRay’s MRIdian magnetic resonance imaging (MRI)-Guided Radiation Therapy System.

The centre aims to accelerate innovations in oncology for all patients in the Hauts-de-France region.

It represents the first location in the region of Lille to provide advanced MRI-guided radiation therapy.

Through diagnostic-quality MR images, ViewRay’s MRIdian system offers better anatomical visualisation to clinicians, as well as the ability to improve targeting precision and provide effective radiation doses.

The combination of the latest innovations in precision radiation therapy, advanced MR image guidance and on-table adaptive therapy will allow physicians to define tight treatment margins and avoid unnecessary radiation exposure for healthy tissue, in addition to at-risk organs.

It also allows ablative radiation doses to be provided in five or fewer treatment sessions, without depending on implanted markers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MRIdian provides real-time continuous tracking of the target and at-risk organs, allowing automatic gating of the radiation beam if the target moves outside the user-defined margins.

This allows prescribed dose delivery to the target while surrounding healthy tissue and critical structures are avoided.

It will also reduce the toxicities that are associated with conventional radiation therapy.

ViewRay chief medical officer Martin Fuss said: “With MRIdian, Centre Oscar Lambret will offer personalised treatment to a broader population of cancer patients.

“Through the use of MRI-guidance, on-table adaptive replanning capabilities, and the ability to control the radiation beam based on real-time MR-imaging during treatment, Centre Oscar Lambret will improve the accuracy with which they deliver radiation treatments.

“Patients will benefit from higher radiation doses delivered in fewer treatment sessions, even if they may have tumours that are today considered virtually untreatable.”

Centre Oscar Lambret intends to start treating patients in early 2024.

53 MRIdian radiation therapy systems are currently installed at hospitals worldwide.